期刊文献+

水飞蓟素治疗丙型肝炎疗效的Meta分析

Meta-analysis of silymarin therapy for hepatitis C
下载PDF
导出
摘要 目的系统评价水飞蓟素治疗丙型病毒性肝炎的有效性。方法通过计算机检索PubMed、Medline、Embase、Cochrane图书馆、CBM、VIP、CNKI数据库。按纳入与排除标准选择随机对照实验,对纳入研究的方法学质量进行评价,提取资料。并用RevMan 5.0软件对数据进行分析。结果共纳入10篇文献,在治疗总有效率、血清丙氨酸基转移酶(ALT)方面比较治疗组均优于对照组,差异有统计学意义(P<0.001)。结论水飞蓟素对于丙型肝炎有一定的疗效,可提高总有效率,降低肝酶学指标,提高丙型肝炎患者的治愈率。 Objective To assess the efficacy of silymarin in the treatment of hepatitis C.Methods Data were retrieved from PubMed,Medline,Embase,Cochrane Library,CBM,VIP,CNKI databases.The inclusion and exclusion criteria were used to choose randomized controlled trials,the methodological quality of included studies was evaluated,The RevMan 5.0 software was used for data analysis.Results A total of 10 RCTs were included.The total effective rate,serum alanine transaminase (ALT) were better in silymarin treatment group than those in control group (P <0.001).Conclusion Silymarin has certain curative effect for hepatitis C,it can increase the total effective rate,reduce liver enzyme indicators,improve the curative rate of hepatitis C.
作者 王琳 陈茂伟
出处 《胃肠病学和肝病学杂志》 CAS 2013年第11期1144-1146,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 水飞蓟素 丙型肝炎 系统评价 META分析 Silymarin Hepatitis C System evaluation Meta analysis
  • 相关文献

参考文献16

  • 1Polyak SJ, Morishima C, Hawke R. Antiviral effects of silymarin a- gainst hepatitis C: the jury is still out [ J]. Hepatology, 2008, 48 ( 1 ) : 345-346.
  • 2Barbero-Becerra V J, M6ndez-S6nchez N. Silybin/Silymarin treatment in chronic hepatitis C [J]. Ann Hepatol, 2012, 11(5): 731-733.
  • 3Fried MW, Navarro V J, Afdhal N, et at. Effect of silymarin ( milk thistle) on liver disease in patients with chronic hepatitis C unsuccess- fully treated with interferon therapy : a randomized controlled trial [ J ]. JAMA, 2012, 308(3) : 274-282.
  • 4Yakoot M, Salem A. Spirulina platensis versus silymarin in the treat- ment of chronic hepatitis C virus infection. A pilot randomized, 'om- parative clinical trial [ J]. BMC Gastroenterol, 2012, 12: 32.
  • 5Rutter K, Scherzer TM, Beinhardt S, et al. Intravenous silibinin as rescue treatment'for on-treatment non-responders to pegylated interfer on/ribavirin combination therapy [ J ]. Antivir Ther, 2011, 16 ( 8 ) 1327-1333.
  • 6Hawke RL, Sehrieber SJ, Soule TA, et al. Silymarin ascending multi- pie oral dosing phase I study in noncirrhotic patients with chronic h,p- titis C [J]. J Clin Pharmacol, 2010, 50(4): 434449.
  • 7P6r A, Roth E, Miseta A, et al. Effects of supplementation with th antioxidant fiavonoid, silymarin, in chronic hepatitis C patients treatc with peg-interferon + ribavirin. A placebo-controlled double blin study [J]. Orv Hetil, 2009, 150(2):73-79.
  • 8Huber R, Futter I, Ltidtke R. Oral silymarin for chronic hepatitis C-l retrospective analysis comparing three dose regimens [ J ]. Eur J Med Res, 2005, 10(2): 68-70.
  • 9Tanamly MD, Tadros F, Labeeb S, et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian villag++: study description and 12-month results [ J]. Dig Liver Dis, 2004, 36 ( 11 ) :752-759.
  • 10Kalantari H. Effects of silybum marianum on patients with chronic" hepatitis C [J]. J Res Med Sci, 2011, 16(3): 287-290.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部